Combined chemotherapy of hydroxycampothecin with oxaliplatin as an adjuvant treatment for human Colorectal cancer

Tohoku Journal of Experimental Medicine

Volumn 215, Issue 3, 2008, Pages 267-278

  Yao, Yang ^a   Zhao, Hui ^a   Sun, Yunjue ^a   Lin, Feng ^a   Tang, Lila ^a   Chen, Ping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Apoptosis; Chemotherapy; Colorectal cancer; Hydroxycampothecin; Oxaliplatin

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; FAS LIGAND; FLUOROURACIL; FOLINIC ACID; HYDROXYCAMPTOTHECIN; OXALIPLATIN; PROTEIN P53;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KIDNEY INJURY; LEUKOPENIA; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PERIPHERAL NEUROPATHY; PROTEIN EXPRESSION; SURVIVAL RATE; THROMBOCYTOPENIA; TUMOR VOLUME; TUMOR XENOGRAFT; VOMITING;

ADJUVANTS, PHARMACEUTIC; ADULT; AGED; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CAMPTOTHECIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MICE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; ORGANOPLATINUM COMPOUNDS;

EID: 48949092073     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.215.267     Document Type: Article

References (21)

1. Alici, S., Aykan, N.F., Sakar, B., Bulutlar, G., Kaytan, E. & Topuz, E. (2003) Colorectal Cancer in Young Patients: Characteristics and Outcome. Tohoku J. Exp. Med., 199, 85-93.
2. Baas, I.O., Mulder, J.W., Offerhaus, G.J., Vogelstein, B. & Hamilton, S.R. (1994) An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J. Pathol., 172, 5-12.
3. Bailly, C. (2003) Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit. Rev. Oncol. Hematol., 45, 91-108.
4. Bossi, G. & Sacchi, A. (2007) Restoration of wild-type P53 function in human cancer: relevance for tumor therapy. Head Neck, 29, 272-284.
5. Demarquay, D., Huchet, M., Coulomb, H., Lesueur-Ginot, L., Lavergne, O., Camara, J., Kasprzyk, P.G., Prévost, G. & Bigg, D.C. (2004) BN80927: a novel homocamptothecin that inhibits proliferation of human cells in vitro and in vivo. Cancer Res., 64, 4942-4949.
6. Gennari, L., Russo, A. & Rossetti, C. (2007) Colorectal cancer: what has changed in diagnosis and treatment over the last 50 years? Tumori., 93, 235-241.
7. Giles, G.I. & Sharma, R.P. (2005) Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Med. Chem., 1, 383-394.
8. Harris, C.C. & Hollstein, M. (1993) Clinical implications of the p53 tumor suppressor gene. N. Engl. J. Med., 329, 1318-1327.
9. O'Brien, D.I., Nally, K., Kelly, R.G., O'Connor, T.M., Shanahan, F. & O'Connell, J. (2005) Targeting the Fas/Fas ligand pathway in cancer. Expert. Opin. Ther. Targets., 9, 1031-1044.
10. O'Dwyer, P.J. & Johnson, S.W. (2003) Current status of oxaliplatin in colorectal cancer. Semin. Oncol., 30, 78-87.
11. Pelley, R.J. (2001) Oxaliplatin: a new agent for colorectal cancer. Curr. Oncol. Rep., 3, 147-155.
12. Reddy, B.S. (2007) Strategies for colon cancer prevention: combination of chemopreventive agents. Subcell Biochem., 42, 213-225.
13. Rothenberg, M.L., Oza, A.M., Bigelow, R.H., Berlin, J.D., Marshall, J.L., Ramanthan, R.K., Hart, L.L., Gupta, S., Garay, C.A., Burger, B.G., Le Bail, N. & Haller, D.G. (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J. Clin. Oncol., 21, 2059-2069.
14. Rougier, P., Lepille, D., Bennouna, J., Marre, A., Ducreux, M., Mignot, L., Hua, A. & Méry-Mignard, D. (2002) Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-Fu regimen failure: a randomized, multicentre phase II study. Ann. Oncol., 13, 1558-1567.
15. Sobin, L.H. & Wittekind, C.H. (1997) International Union Against Cancer (UICC): TNM classification of malignant tumors. 5th ed., Wiley-Liss, New York, NY.
16. Soong, R., Powell, B., Elsaleh, H., Gnanasampanthan, G., Smith, D.R., Goh H.S., Joseph, D. & Iacopetta, B. (2000) Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumor site, stage, adjuvant chemotherapy, and type of mutation. Eur. J. Cancer, 36, 2053-2060.
17. Tu, S.P., Zhong, J., Tan, J.H., Jiang, X.H., Qiao, M.M., Wu, Y.X. & Jiang, S.H. (2000) Induction of apoptosis by arsenic trioxide and hydroxyl camptothecin in gastri-cancer cells in vitro. World J. Gastroenterol., 6, 532-539.
18. Urasaki, Y., Takebayashi Y. & Pommier, Y. (2000) Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations. Cancer Res., 60, 6577-6580.
19. Yoong, K.F., Afford, S.C., Randhawa, S., Hubscher, S.G. & Adams, D.H. (1999) Fas/Fas ligand interaction in human colorectal hepatic metastases: A mechanism of hepatocyte destruction to facilitate local tumor invasion. Am. J. Pathol., 154, 693-703.
20. Zhang, R., Li, Y., Cai, Q., Liu, T., Sun, H. & Chambless, B. (1998) Preclinic pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I. Cancer Chemother. Pharmacol., 41, 257-267.
21. Zhang, X.W., Zhou, Y.H. & Xu, B. (2000) Differentiation of human Hep G2 cells induced by 10-hydroxycamptothecin. Chin. Med. J., 113, 712-713.